Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 52

Sort by

Sort Order Select

Journal Articles

How I treat acute myeloid leukemia in the era of new drugs

Courtney D. DiNardo, Andrew H. Wei

Blood (2020) 135 (2): 85–96.

https://doi.org/10.1182/blood.2019001239

Published: 2020

Includes: Supplemental data

Journal Articles

PP2A Activators Enhance Efficacy of FLT3 Inhibitors in FLT3-ITD Acute Myeloid Leukemia Cells through AKT Inactivation-Dependent Pim-1 and c-Myc Proteasomal Degradation

Mario Scarpa, PhD, Prerna Singh, MS, Shivani Kapoor, MS, Jonelle K. Lee, MS, Sandrine Niyongere, MD, Goutham Narla, MD PhD, Danilo Perrotti, MD PhD, Maria R. Baer, MD

Blood (2019) 134 (Supplement_1): 1276.

https://doi.org/10.1182/blood-2019-129011

Published: 2019

Journal Articles

Somatic Mutations Potentiating RAS-MAPK Signaling Confer Resistant Potential Against FLT3-Inhibitors to Acute Myelogenous Leukemia

Masayasu Hayashi, MD PhD, Yoshikane Kikushige, MD PhD, Takuya Harada, MD, Toshihiro Miyamoto, MD PhD, Takahiro Maeda, MD PhD, Koichi Akashi, MD PhD

Blood (2019) 134 (Supplement_1): 910.

https://doi.org/10.1182/blood-2019-130694

Published: 2019

Journal Articles

Phase II Randomized Trial of Gilteritinib Vs Midostaurin in Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML)

Selina M. Luger, MD FRCPC, Zhuoxin Sun, PhD, Sanam Loghavi, MD, Hillard M Lazarus, MD, Jacob M. Rowe, MB, BS, Martin S. Tallman, MD, Keith W. Pratz, MD, Mark Litzow, MD

Blood (2019) 134 (Supplement_1): 1309.

https://doi.org/10.1182/blood-2019-128377

Published: 2019

Journal Articles

Emerging Mutations at Relapse in Patients with FLT3 -Mutated Relapsed/Refractory Acute Myeloid Leukemia Who Received Gilteritinib Therapy in the Phase 3 Admiral Trial

Catherine C. Smith, MD, Mark J. Levis, MD, Alexander E. Perl, MD, Giovanni Martinelli, MD, Andreas Neubauer, MD, Ellin Berman, MD, Pau Montesinos, MD PhD, Maria R. Baer, MD, Richard A. Larson, MD, Wen-Chien Chou, MD, PhD, Hisayuki Yokoyama, MD PhD, Christian Recher, MD PhD, Sung-Soo Yoon, MD PhD, Jason E. Hill, Matt Rosales, Erkut Bahceci

Blood (2019) 134 (Supplement_1): 14.

https://doi.org/10.1182/blood-2019-122620

Published: 2019

Journal Articles

Preclinical Evaluation of Gilteritinib on NPM1-ALK Driven Anaplastic Large Cell Lymphoma Cells

Sudhakiranmayi Kuravi, M.S., Janice Cheng, MD, Kishore Polireddy, PhD, Gabrielle Fangman, B.S., Roy A Jensen, MD, Tara L. Lin, MD, Siddhartha Ganguly, MD, Joseph P. McGuirk, DO, Ramesh Balusu, PhD

Blood (2019) 134 (Supplement_1): 2865.

https://doi.org/10.1182/blood-2019-130633

Published: 2019

Journal Articles

Individualized Mitochondrial Functional Approach to Combination of BCL-2 and MCL-1 Antagonism in Acute Myeloid Leukemia

Shruti Bhatt, PhD, Marissa Pioso, Elyse Ann Olesinski, Binyam Yilma, Leutz Buon, Sophia Adamia, PhD, Holly Zhu, Jeremy Ryan, Youzhen Wang, Morris Erick, Ensar Halilovic, David M. Weinstock, MD, Jacqueline S Garcia, MD, Anthony Letai

Blood (2019) 134 (Supplement_1): 2551.

https://doi.org/10.1182/blood-2019-131101

Published: 2019

Journal Articles

Ex-Vivo Drug Response Profiling for Tailoring Treatment in Hematologic Malignancies: The Prospective Non-Interventional SMART-Trial

Nora Liebers, Peter-Martin Bruch, Agnes Gambietz, Holly Giles, BA, Junyan Lu, PhD, Mareike Knoll, Carolin Kolb, Peter Dreger, Carsten Mueller-Tidow, MD, Wolfgang Huber, PhD, Axel Benner, Thorsten Zenz, MD, Sascha Dietrich, MD

Blood (2019) 134 (Supplement_1): 376.

https://doi.org/10.1182/blood-2019-125324

Published: 2019

Journal Articles

High Dependence on Medicare and Foundation Grant Assistance Among Patients with Hematologic Malignancies Receiving Novel Oral Therapeutics

Erlene K. Seymour, MD, Lucius Daniel, Eva Pointer, MS, Stephen T. Smith, Charles A. Schiffer, MD

Blood (2019) 134 (Supplement_1): 64.

https://doi.org/10.1182/blood-2019-128905

Published: 2019

Journal Articles

Cost-Effectiveness Analysis of Gilteritinib Versus Salvage Chemotherapy (SC) for the Treatment of Relapsed or Refractory (R/R) FLT3 -Mutated ( FLT3 mut+ ) Acute Myeloid Leukemia (AML)

Amer M. Zeidan, MBBS, MHS, Cynthia Z. Qi, MBA, Bhavik J. Pandya, PharmD, Andy Garnham, Hongbo Yang, Manasee V Shah, MPH

Blood (2019) 134 (Supplement_1): 3859.

https://doi.org/10.1182/blood-2019-123819

Published: 2019

Journal Articles

Venetoclax in Combination with Gilteritinib in Patients with Relapsed/Refractory Acute Myeloid Leukemia: A Phase 1b Study

Alexander E. Perl, MD, Naval G. Daver, MD, Keith W. Pratz, MD, Joseph Maly, MD, Wan-Jen Hong, MD, Erkut Bahceci, Bo Tong, PhD, Tian Tian, PhD, Kimberley Dilley, MD MPH

Blood (2019) 134 (Supplement_1): 3910.

https://doi.org/10.1182/blood-2019-127416

Published: 2019

Journal Articles

The Relationship between Transplant Status and Patient-Reported Outcomes in Patients with FLT3 -Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML): Results from the Phase 3 Admiral Study

David Cella, PhD, Ellen K. Ritchie, MD, Francesco Fabbiano, Arnaud Pigneux, Yoshinobu Kanda, MD PhD, Cristina Ivanescu, PhD, Bhavik J. Pandya, PharmD, Manasee V Shah, MPH

Blood (2019) 134 (Supplement_1): 3850.

https://doi.org/10.1182/blood-2019-123790

Published: 2019

Journal Articles

Streamline - Study of Relapse or Refractory (R/R) FLT3 -Mutated Acute Myeloid Leukemia (AML) Using Electronic Medical Records (EMR): First Analysis from a Multicenter, Retrospective Cohort Study

Amer M. Zeidan, MBBS, MHS, Adrienne Gilligan, PhD, Santosh Gautam, Nan Hu, David L. Grinblatt, Bhavik J. Pandya, PharmD

Blood (2019) 134 (Supplement_1): 5082.

https://doi.org/10.1182/blood-2019-123535

Published: 2019

Journal Articles

ETH-155008, a Novel Selective Dual Inhibitor of FLT3 and CDK4/6 in Preclinical Treatment of Acute Myeloid Leukemia

Changnian Liu, PhD MD, Bin Liu, MSc, Chunping Xu, PhD, Pan Zhang, Bin Li, Bin Ji, Bin Zhang, Qingjun Liu, PhD, James Zhang, MSc, Chengzhi Yu, PhD

Blood (2019) 134 (Supplement_1): 5141.

https://doi.org/10.1182/blood-2019-123589

Published: 2019

Journal Articles

Cost-Effectiveness Analysis of Gilteritinib Versus Best Supportive Care (BSC) for the Treatment of Relapsed or Refractory (R/R) FLT3 Mutation-Positive ( FLT3 mut+ ) Acute Myeloid Leukemia (AML)

Amer M. Zeidan, MBBS, MHS, Bhavik J. Pandya, PharmD, Cynthia Z. Qi, MBA, Andy Garnham, Hongbo Yang, Manasee V Shah, MPH

Blood (2019) 134 (Supplement_1): 5085.

https://doi.org/10.1182/blood-2019-123811

Published: 2019

Journal Articles

BMT CTN Protocol 1506: A Phase 3 Trial of Gilteritinib As Maintenance Therapy after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with FLT3- ITD + AML

Mark J. Levis, MD, Mehdi Hamadani, MD, Brent R. Logan, Matt Rosales, David Delgado, Erkut Bahceci, Steven Devine, MD, Mary M. Horowitz, Yi-Bin Chen

Blood (2019) 134 (Supplement_1): 4602.

https://doi.org/10.1182/blood-2019-124322

Published: 2019

Journal Articles

The Ever-Changing Therapeutic Landscape of AML: A Real World Experience of Novel Therapies on Outcomes

Abhay Singh, MBBS, MPH, Sarah Sadek, MD, Mark G. Faber, DO, Jeffrey Baron, PharmD, James E. Thompson, MD, Amanda Przespolewski, DO, Elizabeth A. Griffiths, MD, Eunice S. Wang, MD, Swapna Thota, MD

Blood (2019) 134 (Supplement_1): 5095.

https://doi.org/10.1182/blood-2019-132040

Published: 2019

Journal Articles

The Combination of CUDC-907 and Gilteritinib Shows Promising Antileukemic Activity in Vitro and In Vivo in Preclinical Models of FLT3-ITD AML

Tristan Knight, MD, Xinan Qiao, BS, Jun Ma, Holly Edwards, BS, Lisa Polin, PhD, Juiwanna Kushner, Sijana H Dzinic, PhD, Kathryn White, Hai Lin, MD, Yue Wang, Jeffrey W. Taub, MD, Yubin Ge, PhD

Blood (2019) 134 (Supplement_1): 1262.

https://doi.org/10.1182/blood-2019-123793

Published: 2019

Journal Articles

Cage Transcriptome Analysis Reveals BCL2A1 Upregulation in FLT3 -ITD/D835 Dual Mutated AML Cells Harboring Complex Co-Mutations

Kotoko Yamatani, MD, Tomohiko Ai, MD PhD, Kaori Saito, Haeun Yang, Koya Suzuki, PhD, Atsushi Hori, PhD, Yuko Murakami-Tonami, MD PhD, Weiguo Zhang, MD PhD, Bing Z Carter, PhD, Sonoko Kinjo, PhD, Kazuho Ikeo, PhD, Katayama Kazuhiro, Hironori Harada, MD PhD, Takashi Miida, MD PhD, Neil P. Shah, MD PhD, Marina Y Konopleva, MD PhD, Yoshihide Hayashizaki, MD PhD, Michael Andreeff, MD PhD, Yoko Tabe, MD PhD

Blood (2019) 134 (Supplement_1): 1264.

https://doi.org/10.1182/blood-2019-124685

Published: 2019

Journal Articles

Inhibition of Mcl-1 Enhances the Efficacy of Tyrosine Kinase Inhibition in FLT3 Mutated AML and Synergizes with Venetoclax Targeting AML Stem Cells

Bing Z Carter, PhD, Wenjing Tao, Po Yee Mak, Qi Zhang, PhD, Xiangmeng Wang, Vinitha Mary Kuruvilla, MSc, Carli Stewart, Vivian Ruvolo, MS, Venkata Lokesh Battula, PhD, Marina Y Konopleva, MD PhD, Sean Caenepeel, Jude Canon, PhD, Paul Hughes, PK Morrow, Michael Andreeff, MD PhD

Blood (2019) 134 (Supplement_1): 1267.

https://doi.org/10.1182/blood-2019-125725

Published: 2019

NARROW

How I treat acute myeloid leukemia in the era of new drugs

PP2A Activators Enhance Efficacy of FLT3 Inhibitors in FLT3-ITD Acute Myeloid Leukemia Cells through AKT Inactivation-Dependent Pim-1 and c-Myc Proteasomal Degradation

Somatic Mutations Potentiating RAS-MAPK Signaling Confer Resistant Potential Against FLT3-Inhibitors to Acute Myelogenous Leukemia

Phase II Randomized Trial of Gilteritinib Vs Midostaurin in Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML)

Emerging Mutations at Relapse in Patients with FLT3 -Mutated Relapsed/Refractory Acute Myeloid Leukemia Who Received Gilteritinib Therapy in the Phase 3 Admiral Trial

Preclinical Evaluation of Gilteritinib on NPM1-ALK Driven Anaplastic Large Cell Lymphoma Cells

Individualized Mitochondrial Functional Approach to Combination of BCL-2 and MCL-1 Antagonism in Acute Myeloid Leukemia

Ex-Vivo Drug Response Profiling for Tailoring Treatment in Hematologic Malignancies: The Prospective Non-Interventional SMART-Trial

High Dependence on Medicare and Foundation Grant Assistance Among Patients with Hematologic Malignancies Receiving Novel Oral Therapeutics

Cost-Effectiveness Analysis of Gilteritinib Versus Salvage Chemotherapy (SC) for the Treatment of Relapsed or Refractory (R/R) FLT3 -Mutated ( FLT3 mut+ ) Acute Myeloid Leukemia (AML)

Venetoclax in Combination with Gilteritinib in Patients with Relapsed/Refractory Acute Myeloid Leukemia: A Phase 1b Study

The Relationship between Transplant Status and Patient-Reported Outcomes in Patients with FLT3 -Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML): Results from the Phase 3 Admiral Study

Streamline - Study of Relapse or Refractory (R/R) FLT3 -Mutated Acute Myeloid Leukemia (AML) Using Electronic Medical Records (EMR): First Analysis from a Multicenter, Retrospective Cohort Study

ETH-155008, a Novel Selective Dual Inhibitor of FLT3 and CDK4/6 in Preclinical Treatment of Acute Myeloid Leukemia

Cost-Effectiveness Analysis of Gilteritinib Versus Best Supportive Care (BSC) for the Treatment of Relapsed or Refractory (R/R) FLT3 Mutation-Positive ( FLT3 mut+ ) Acute Myeloid Leukemia (AML)

BMT CTN Protocol 1506: A Phase 3 Trial of Gilteritinib As Maintenance Therapy after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with FLT3- ITD + AML

The Ever-Changing Therapeutic Landscape of AML: A Real World Experience of Novel Therapies on Outcomes

The Combination of CUDC-907 and Gilteritinib Shows Promising Antileukemic Activity in Vitro and In Vivo in Preclinical Models of FLT3-ITD AML

Cage Transcriptome Analysis Reveals BCL2A1 Upregulation in FLT3 -ITD/D835 Dual Mutated AML Cells Harboring Complex Co-Mutations

Inhibition of Mcl-1 Enhances the Efficacy of Tyrosine Kinase Inhibition in FLT3 Mutated AML and Synergizes with Venetoclax Targeting AML Stem Cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only